Mihaela Aldea

TL;DR: This approach could offer a new chemotherapy strategy for patients diagnosed with unresectable hepatocellular carcinoma (HCC) and proposes a novel platform therapy with minimal toxicity and increased efficacy profiles for the destruction of hepatic cancer cells.

TL;DR: An overview of resistance to tumor and immune-targeted therapies and challenges of overcoming resistance, and current and future directions of development are discussed in this paper, where a better and earlier identification of cancer-resistance mechanisms could avoid the use of ineffective drugs in patients not responding to therapy and provide the rationale for the administration of personalized drug associations.

TL;DR: In this article, the authors summarized the available clinical and preclinical evidence for the role of tumour burden in determining the outcomes of patients receiving immune-checkpoint inhibitors and highlighted areas that are likely to be of future research interest in this emerging area.

TL;DR: Although tagged amplicon-based NGS has high detection rates of GA in plasma ctDNA in NSCLC patients with extraCNS disease, detection rate of GAs is lower in the subset of iCNS patients, suggesting complementary tests, such as CSF cell-free DNA, may be useful.

TL;DR: The potential employment of metformin and arsenic trioxide (ATO) in glioblastoma therapy is discussed focusing on their effects on GSC.